Bone Tissue Engineering in a Perfusion Bioreactor Using Dexamethasone-Loaded Peptide Hydrogel.

Area of Science:

• Biomaterials Science
• Tissue Engineering
• Regenerative Medicine

Background:

• Bone tissue engineering aims to regenerate bone defects using scaffolds and cells.
• Controlling drug release from scaffolds is crucial for guiding cell differentiation.
• Human mesenchymal stem cells (hMSCs) are a promising cell source for bone regeneration.

Purpose of the Study:

• To create bone tissue using dexamethasone (DEX)-loaded RADA 16-I scaffolds under perfusion.
• To determine the optimal DEX concentration for bone formation.
• To evaluate the potential of this system in regenerative orthopedics.

Main Methods:

• hMSCs were isolated and seeded onto DEX-loaded RADA 16-I scaffolds.
• Scaffolds were cultured in a perfusion bioreactor for 21 days with varying DEX concentrations (4 × 10^-3, 4 × 10^-4, 4 × 10^-5 M).
• Osteogenic differentiation was assessed using SEM, histology, RT-PCR, immunocytochemistry, and von Kossa staining.

Main Results:

• The RADA 16-I scaffold loaded with 4 × 10^-4 M DEX demonstrated optimal engineered bone tissue morphology.
• Osteogenic gene expression (ALP, COL1A1, OC) and mineral deposition were confirmed.
• SEM and histology showed mature bone tissue characteristics, including cells, extracellular matrix, and minerals.

Conclusions:

• Dexamethasone-loaded RADA 16-I scaffolds under perfusion effectively promote hMSC osteogenic differentiation.
• A DEX concentration of 4 × 10^-4 M is optimal for engineered bone tissue formation.
• This approach shows significant potential for applications in regenerative orthopedics.